Publications
Detailed Information
Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyo Jin | - |
dc.contributor.author | Kim, Hyunsuk | - |
dc.contributor.author | Shin, Nara | - |
dc.contributor.author | Na, Ki Young | - |
dc.contributor.author | Kim, Yong Lim | - |
dc.contributor.author | Kim, Daejung | - |
dc.contributor.author | Chang, Jae Hyun | - |
dc.contributor.author | Song, Young Rim | - |
dc.contributor.author | Hwang, Young-Hwan | - |
dc.contributor.author | Kim, Yon Su | - |
dc.contributor.author | Ahn, Curie | - |
dc.contributor.author | Lee, Joongyub | - |
dc.contributor.author | Oh, Kook-Hwan | - |
dc.contributor.author | Representing the Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect Of iPTH Level (CUPID) Study Group | - |
dc.date.accessioned | 2013-06-03T06:37:32Z | - |
dc.date.available | 2013-06-03T06:37:32Z | - |
dc.date.issued | 2013-05-25 | - |
dc.identifier.citation | BMC Nephrology, Vol.14, No.112 | ko_KR |
dc.identifier.issn | 1471-2369 | - |
dc.identifier.uri | http://www.biomedcentral.com/1471-2369/14/112 | - |
dc.identifier.uri | https://hdl.handle.net/10371/82587 | - |
dc.description.abstract | Background : Elevated serum level of fibroblast growth factor-23 (FGF23) is associated with adverse outcomes in dialyzed patients. Objectives : The CUPID study compared the efficacy of a cinacalcet-based regimen with conventional care (vitamin D and P binders) for achieving the stringent NKF-K/DOQI targets for peritoneal dialysis (PD) patients. Additionally, we analyzed change in FGF23 levels between two treatments to explore the cinacalcet effect in lowering FGF23. Design : Multicenter, open-labeled, randomized controlled study. Setting : Seven university-affiliated hospitals in Korea. Participants : Overall, 66 peritoneal dialysis patients were enrolled. Intervention : Sixty six patients were randomly assigned to treatment with either cinacalcet + oral vitamin D (cinacalcet group, n = 33) or oral vitamin D alone (control group, n = 33) to achieve K/DOQI targets. CUPID included a 4-week screening for vitamin D washout, a 12-week dose-titration, and a 4-week assessment phases. We calculated mean values of iPTH, Ca, P, Ca x P, during assessment phase and final FGF23 to assess the outcome. Main outcome measures : Achievement of >30% reduction of iPTH from baseline (primary) and FGF23 reduction (secondary). Results : 72.7% (n = 24) of the cinacalcet group and 93.9% (n = 31) of the control group completed the study. Cinacalcet group received 30.2 ± 18.0 mg/day of cinacalcet and 0.13 ± 0.32 μg/d oral vitamin D (P < 0.001 vs. control with 0.27 ± 0.18 μg/d vitamin D). The proportion of patients who reached the primary endpoint was not statistically different (48.5% vs. 51.5%, cinacalcet vs. control, P = 1.000). After treatment, cinacalcet group experienced a significant reduction in FGF23 levels (median value from 3,960 to 2,325 RU/ml, P = 0.002), while an insignificant change was shown for control group (from 2,085 to 2,415 RU/ml). The percent change of FGF23 after treatment was also significantly different between the two groups (− 42.54% vs. 15.83%, P = 0.008). After adjustment, cinacalcet treatment was independently associated with the serum FGF23 reduction. Conclusion : Cinacalcet treatment was independently associated with the reduction of FGF23 in our PD patients. | ko_KR |
dc.description.sponsorship | The CUPID study was funded by Kyowa Kirin, Korea. However, the funding body had no role in the design, implementation, analysis of the study. Presented at the Kidney Week 2012 of the American Society of Nephrology, San Diego, CA, October 30- November 4, 2012. We thank the Medical Research Collaborating Center (MRCC), Seoul National University Hospital for the statistical advice. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | ko_KR |
dc.subject | Cinacalcet | ko_KR |
dc.subject | Fibroblast growth factor 23 | ko_KR |
dc.subject | Peritoneal dialysis | ko_KR |
dc.title | Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김효진 | - |
dc.contributor.AlternativeAuthor | 김현석 | - |
dc.contributor.AlternativeAuthor | 신나라 | - |
dc.contributor.AlternativeAuthor | 나기영 | - |
dc.contributor.AlternativeAuthor | 김용림 | - |
dc.contributor.AlternativeAuthor | 김대정 | - |
dc.contributor.AlternativeAuthor | 장재현 | - |
dc.contributor.AlternativeAuthor | 송영림 | - |
dc.contributor.AlternativeAuthor | 황영환 | - |
dc.contributor.AlternativeAuthor | 김연수 | - |
dc.contributor.AlternativeAuthor | 이중엽 | - |
dc.contributor.AlternativeAuthor | 오국환 | - |
dc.contributor.AlternativeAuthor | 안규리 | - |
dc.identifier.doi | 10.1186/1471-2369-14-112 | - |
dc.language.rfc3066 | en | - |
dc.description.version | Peer Reviewed | - |
dc.rights.holder | Hyo Kim et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2013-05-31T15:16:28Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.